Ceryvyn Therapeutics (ASX:CYV) Total Debt per Share: A$0.00 (As of Jun. 2025)


What is Ceryvyn Therapeutics Total Debt per Share?

Ceryvyn Therapeutics ASX:CYV -7.69% Total Debt per Share is A$0.00 as of Jun. 2025. The stock has 3 warning signs investors should review.

A$0.00 (As of Jun. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Ceryvyn Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2025 was A$0.00.

Ceryvyn Therapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Total Debt per Share Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.24 0.20 0.00

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.00 0.20 0.20 0.00

Ceryvyn Therapeutics Total Debt per Share Calculation

Ceryvyn Therapeutics's Total Debt Per Share for the fiscal year that ended in Jun. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+0.00)/1,231.82
=0.00

Ceryvyn Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+0.00)/1,231.82
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of A$0.00 mean?
Ceryvyn Therapeutics (ASX:CYV) has a Total Debt per Share of A$0.00 as of Jun. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Total Debt per Share too high?
Ceryvyn Therapeutics' current Total Debt per Share is A$0.00.
How does Ceryvyn Therapeutics' Total Debt per Share compare to VRTX and REGN?
Ceryvyn Therapeutics' Total Debt per Share of A$0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Total Debt per Share is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Total Debt per Share of A$0.00. The current Total Debt per Share is A$0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Total Debt per Share is A$0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.